{
  "$schema": "folio-library-document/v1",
  "id": "10665-342365",
  "title": "WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
  "variant": "pdf",
  "pages": 115,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Contents",
      "number": null,
      "page": 4,
      "pageLabel": "iii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-contents"
    },
    {
      "level": 1,
      "title": "Acronyms and abbreviations",
      "number": null,
      "page": 8,
      "pageLabel": "vii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-acronyms-and-abbreviations"
    },
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 6,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-acknowledgements"
    },
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 9,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-executive-summary"
    },
    {
      "level": 2,
      "title": "Background",
      "number": null,
      "page": 9,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-background"
    },
    {
      "level": 2,
      "title": "Methods",
      "number": null,
      "page": 9,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-methods"
    },
    {
      "level": 2,
      "title": "Summary of screening and treatment recommendations to prevent cervical cancer",
      "number": null,
      "page": 11,
      "pageLabel": "x",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-summary-of-screening-and-treatment-recommendatio"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "1",
      "page": 18,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-1-introduction"
    },
    {
      "level": 2,
      "title": "Background",
      "number": "1.1",
      "page": 18,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-11-background"
    },
    {
      "level": 2,
      "title": "Approaches to screening and treatment",
      "number": "1.2",
      "page": 20,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-12-approaches-to-screening-and-treatment"
    },
    {
      "level": 2,
      "title": "Rationale for this new edition of recommendations",
      "number": "1.3",
      "page": 21,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-13-rationale-for-this-new-edition-of-recommendat"
    },
    {
      "level": 2,
      "title": "Phased approach for the development of the recommendations",
      "number": "1.4",
      "page": 22,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-14-phased-approach-for-the-development-of-the-re"
    },
    {
      "level": 2,
      "title": "Target audience",
      "number": "1.5",
      "page": 23,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-15-target-audience"
    },
    {
      "level": 1,
      "title": "Methods",
      "number": "2",
      "page": 24,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-2-methods"
    },
    {
      "level": 2,
      "title": "Groups contributing to the guideline development process",
      "number": "2.1",
      "page": 24,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-21-groups-contributing-to-the-guideline-developm"
    },
    {
      "level": 3,
      "title": "Declarations and management of conflicts of interest",
      "number": null,
      "page": 25,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-declarations-and-management-of-conflicts-of-inte"
    },
    {
      "level": 3,
      "title": "Confidentiality",
      "number": null,
      "page": 25,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-confidentiality"
    },
    {
      "level": 2,
      "title": "Scoping review and appraisal of the existing recommendations",
      "number": "2.2",
      "page": 26,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-22-scoping-review-and-appraisal-of-the-existing"
    },
    {
      "level": 2,
      "title": "Priority questions for review of evidence",
      "number": "2.3",
      "page": 27,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-23-priority-questions-for-review-of-evidence"
    },
    {
      "level": 2,
      "title": "Priority algorithms",
      "number": "2.4",
      "page": 28,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-24-priority-algorithms"
    },
    {
      "level": 2,
      "title": "Outcomes",
      "number": "2.5",
      "page": 28,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-25-outcomes"
    },
    {
      "level": 2,
      "title": "Syntheses of evidence",
      "number": "2.6",
      "page": 29,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-26-syntheses-of-evidence"
    },
    {
      "level": 3,
      "title": "Methods used for systematic literature reviews",
      "number": "2.6.1",
      "page": 32,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-261-methods-used-for-systematic-literature-revie"
    },
    {
      "level": 3,
      "title": "Individual patient data meta-analysis",
      "number": "2.6.2",
      "page": 33,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-262-individual-patient-data-meta-analysis"
    },
    {
      "level": 3,
      "title": "Mathematical modelling",
      "number": "2.6.3",
      "page": 34,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-263-mathematical-modelling"
    },
    {
      "level": 3,
      "title": "Values and preferences",
      "number": "2.6.4",
      "page": 34,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-264-values-and-preferences"
    },
    {
      "level": 3,
      "title": "Feasibility, acceptability, resources and equity considerations",
      "number": "2.6.5",
      "page": 35,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-265-feasibility-acceptability-resources-and-equi"
    },
    {
      "level": 2,
      "title": "Development of the recommendations",
      "number": "2.7",
      "page": 35,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-27-development-of-the-recommendations"
    },
    {
      "level": 2,
      "title": "Management of the external peer review",
      "number": "2.8",
      "page": 36,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-28-management-of-the-external-peer-review"
    },
    {
      "level": 1,
      "title": "Important considerations for the recommendations",
      "number": "3",
      "page": 37,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-3-important-considerations-for-the-recommendatio"
    },
    {
      "level": 2,
      "title": "Programme considerations",
      "number": "3.1",
      "page": 37,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-31-programme-considerations"
    },
    {
      "level": 2,
      "title": "Screening and triage tests considered in these guidelines",
      "number": "3.2",
      "page": 38,
      "pageLabel": "21",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-32-screening-and-triage-tests-considered-in-thes"
    },
    {
      "level": 2,
      "title": "Treatment considerations",
      "number": "3.3",
      "page": 40,
      "pageLabel": "23",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-33-treatment-considerations"
    },
    {
      "level": 1,
      "title": "Recommendations and good practice statements on screening and treatment",
      "number": "4",
      "page": 41,
      "pageLabel": "24",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-4-recommendations-and-good-practice-statements-o"
    },
    {
      "level": 2,
      "title": "Recommendations and good practice statements: general population of women",
      "number": "4.1",
      "page": 41,
      "pageLabel": "24",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": null
    },
    {
      "level": 3,
      "title": "Justification",
      "number": "4.1.1",
      "page": 43,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-411-justification"
    },
    {
      "level": 3,
      "title": "Summary of the evidence",
      "number": "4.1.2",
      "page": 45,
      "pageLabel": "28",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-412-summary-of-the-evidence"
    },
    {
      "level": 2,
      "title": "Recommendations and good practice statements: women living with HIV",
      "number": "4.2",
      "page": 48,
      "pageLabel": "31",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-036-42-recommendations-and-good-practice-statements"
    },
    {
      "level": 3,
      "title": "Justification",
      "number": "4.2.1",
      "page": 50,
      "pageLabel": "33",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-411-justification"
    },
    {
      "level": 3,
      "title": "Summary of the evidence",
      "number": "4.2.2",
      "page": 52,
      "pageLabel": "35",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-038-422-summary-of-the-evidence"
    },
    {
      "level": 2,
      "title": "Additional recommendation and good practice statement for treatment not covered",
      "number": "4.3",
      "page": 55,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-039-43-additional-recommendation-and-good-practice-s"
    },
    {
      "level": 3,
      "title": "Justification and evidence summary",
      "number": "4.3.1",
      "page": 55,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-040-431-justification-and-evidence-summary"
    },
    {
      "level": 1,
      "title": "Research gaps and further considerations",
      "number": "5",
      "page": 56,
      "pageLabel": "39",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-041-5-research-gaps-and-further-considerations"
    },
    {
      "level": 1,
      "title": "Dissemination and updating of the guidelines",
      "number": "6",
      "page": 58,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-043-6-dissemination-and-updating-of-the-guidelines"
    },
    {
      "level": 2,
      "title": "Guideline dissemination and impact",
      "number": "6.1",
      "page": 58,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-042-61-guideline-dissemination-and-impact"
    },
    {
      "level": 2,
      "title": "Guideline update",
      "number": "6.2",
      "page": 59,
      "pageLabel": "42",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-044-62-guideline-update"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 60,
      "pageLabel": "43",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-045-references"
    },
    {
      "level": 1,
      "title": "Annexes",
      "number": null,
      "page": 64,
      "pageLabel": "47",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-046-annexes"
    },
    {
      "level": 2,
      "title": "Annex 1: Guideline groups",
      "number": null,
      "page": 65,
      "pageLabel": "48",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-047-annex-1-guideline-groups"
    },
    {
      "level": 2,
      "title": "Annex 2. Evidence-gathering teams and guideline task groups",
      "number": null,
      "page": 75,
      "pageLabel": "58",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-048-annex-2-evidence-gathering-teams-and-guideline-t"
    },
    {
      "level": 2,
      "title": "Annex 3. Declarations of interests",
      "number": null,
      "page": 77,
      "pageLabel": "60",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-049-annex-3-declarations-of-interests"
    },
    {
      "level": 2,
      "title": "Annex 4. Seven algorithms prioritized for Phase 1 of the guideline update",
      "number": null,
      "page": 80,
      "pageLabel": "63",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-050-annex-4-seven-algorithms-prioritized-for-phase-1"
    },
    {
      "level": 2,
      "title": "Annex 5. Standardized definitions used in this guideline",
      "number": null,
      "page": 90,
      "pageLabel": "73",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-051-annex-5-standardized-definitions-used-in-this-gu"
    },
    {
      "level": 2,
      "title": "Annex 6. Additional information for screening and treatment recommendations",
      "number": null,
      "page": 112,
      "pageLabel": "95",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-052-annex-6-additional-information-for-screening-and"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 4,
      "labelStart": "1",
      "labelEnd": "iii",
      "words": 541,
      "summary": {
        "text": "The cover, ISBN and copyright page of the WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition (2021), with licence terms and disclaimers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical pre-cancer",
          "heading": false
        },
        {
          "term": "pre-cancer lesions",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "edition",
          "heading": false
        }
      ],
      "extract": "WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition ISBN 978-92-4-003082-4 (electronic version) ISBN",
      "extractCut": true,
      "blocks": [
        "library/10665-342365/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-contents",
      "number": null,
      "title": "Contents",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 6,
      "labelStart": "iii",
      "labelEnd": "v",
      "words": 837,
      "summary": {
        "text": "The table of contents of the cervical pre-cancer screening and treatment guideline, followed by the start of the acknowledgements listing Guideline Development Group members and evidence contributors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ruanne barnabas",
          "heading": false
        },
        {
          "term": "gdg co-chair",
          "heading": false
        },
        {
          "term": "shona dalal",
          "heading": false
        },
        {
          "term": "nancy santesso",
          "heading": false
        },
        {
          "term": "nathalie broutet",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "external contributors",
          "heading": false
        }
      ],
      "extract": "v Acronyms and abbreviations \b vii Executive summary \b viii Background \b viii Methods \b viii Summary of screening and treatment recommendations to prevent cervical cancer\b x 1. Introduction \b 1 1.1 Background \b 1 1.2 Approaches to screening and treatment \b 3 1.3 Rationale for this new edition of recommendations \b 4 1.4 Phased approach for the development of the recommendations \b 5 1.5 Target audience \b 6 2. Methods",
      "extractCut": true
    },
    {
      "id": "sec-001-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "v",
      "labelEnd": "vii",
      "words": 410,
      "summary": {
        "text": "Continues the acknowledgements of the cervical cancer screening guideline, naming observers, WHO Secretariat members and others, and gives the list of acronyms and abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "undp-unfpa-unicef-who-world bank",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "states president",
          "heading": false
        },
        {
          "term": "states agency",
          "heading": false
        },
        {
          "term": "aids relief",
          "heading": false
        },
        {
          "term": "human reproduction",
          "heading": false
        },
        {
          "term": "acknowledgements",
          "heading": true
        }
      ],
      "extract": "Acknowledgements James Killen, Gigi Lui, Diep Nguyen, Bernardo Nuche, Catherine Sauvaget, Holger Schünemann, Kate Simms, Ronaldo Silva, Karin Sundström, Katayoun Thaghavi, Cari van Schalkwyk and Brian Williams. The following individuals acted as observers at the GDG meeting: Benjamin Anderson, J. (Hans) Berkhof, Smiljka de Lussigny, Eduardo Franco, Lisa Pei-Ching Huang, Krishna Jafa, Jose Jeronimo, Somesh Kumar,",
      "extractCut": true
    },
    {
      "id": "sec-002-acronyms-and-abbreviations",
      "number": null,
      "title": "Acronyms and abbreviations",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 9,
      "labelStart": "vii",
      "labelEnd": "viii",
      "words": 3,
      "summary": {
        "text": "A heading for the acronyms and abbreviations section.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Acronyms and abbreviations",
      "extractCut": false
    },
    {
      "id": "sec-003-background",
      "number": null,
      "title": "Background",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "viii",
      "labelEnd": "viii",
      "words": 211,
      "summary": {
        "text": "Gives the background to the cervical cancer guideline, citing about 604,000 new cases and 342,000 deaths in 2020, mostly in sub-Saharan Africa, Melanesia, South-Eastern Asia and South America. It recalls the Director-General's 2018 call for elimination and the 2020 global strategy targets, and notes that experts agreed to update and simplify screening and treatment recommendations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "leading cause",
          "heading": false
        },
        {
          "term": "global strategy",
          "heading": false
        },
        {
          "term": "director-general",
          "heading": false
        },
        {
          "term": "women",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        }
      ],
      "extract": "Cervical cancer is a leading cause of mortality among women. In 2020, an estimated 604 000 women were diagnosed with cervical cancer worldwide and about 342 000 women died from the disease. Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading cause of cancer death in 36 countries. The vast majority of these countries are in sub-Saharan Africa, Melanesia, South America, and",
      "extractCut": true
    },
    {
      "id": "sec-004-methods",
      "number": null,
      "title": "Methods",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "viii",
      "labelEnd": "viii",
      "words": 16,
      "summary": {
        "text": "A one-line lead-in stating that the updated guideline was developed in three steps.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "This updated guideline for screening and treatment to prevent cervical cancer was developed in three steps:",
      "extractCut": false
    },
    {
      "id": "sec-005-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 11,
      "labelStart": "viii",
      "labelEnd": "x",
      "words": 463,
      "summary": {
        "text": "Lists the three development steps for the cervical cancer guideline: reviewing existing recommendations, framing PICO questions with new or updated systematic reviews and modelling, and applying GRADE with evidence-to-decision tables. It describes the work of the Guideline Development Group from 2019 and defines the screen-and-treat and screen, triage and treat approaches.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "primary screening",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "pico questions",
          "heading": false
        },
        {
          "term": "different screening",
          "heading": false
        }
      ],
      "extract": "1. 2. 3. Review the current guidelines and identify recommendations to update or to develop de novo. Develop questions based on population (P), intervention (I), comparator (C) and outcomes (O) (PICO questions) for the recommendations and conduct new systematic reviews or update those conducted for the previous guideline, and model outcomes when primary research was not available. Apply the Grading of",
      "extractCut": true
    },
    {
      "id": "sec-006-summary-of-screening-and-treatment-recommendatio",
      "number": null,
      "title": "Summary of screening and treatment recommendations to prevent cervical cancer",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 18,
      "labelStart": "x",
      "labelEnd": "1",
      "words": 2450,
      "summary": {
        "text": "Summarises the guideline's 23 recommendations and 7 good practice statements, explaining which apply identically to the general population of women and which differ for women living with HIV. A table pairs the recommendations for each group, starting with the strong recommendation to use HPV DNA detection rather than VIA or cytology as the primary screening test, followed by guidance on triage options, self-collected samples, starting age, screening intervals and follow-up. It gives the strength of each recommendation and certainty of evidence. It ends with summary strategies: HPV DNA screening from age 30 every 5 to 10 years for women generally, and from age 25 every 3 to 5 years with triage for women living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": true
        },
        {
          "term": "prevent cervical",
          "heading": true
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "until hpv",
          "heading": false
        },
        {
          "term": "dna primary",
          "heading": false
        },
        {
          "term": "dna detection",
          "heading": false
        }
      ],
      "extract": "cervical cancer In this present publication, there is a total of 23 recommendations and 7 good practice statements. • Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population. • Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV",
      "extractCut": true
    },
    {
      "id": "sec-007-11-background",
      "number": "1.1",
      "title": "Background",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 382,
      "summary": {
        "text": "Restates the global burden of cervical cancer and the 2030 elimination targets of 90% HPV vaccination, 70% screening and 90% treatment. It explains that cervical intraepithelial neoplasia is caused mainly by high-risk HPV types such as 16 and 18 and distinguishes low-grade lesions from high-grade pre-cancers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cin lesions",
          "heading": false
        },
        {
          "term": "squamous intraepithelial",
          "heading": false
        },
        {
          "term": "leading cause",
          "heading": false
        },
        {
          "term": "global strategy",
          "heading": false
        },
        {
          "term": "correlates",
          "heading": false
        },
        {
          "term": "hpv",
          "heading": false
        },
        {
          "term": "women",
          "heading": false
        }
      ],
      "extract": "Cervical cancer is a leading cause of mortality among women. In 2020, an estimated 604 000 women were diagnosed with cervical cancer worldwide and about 342 000 women died from the disease. Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading cause of cancer death in 36 countries. The vast majority of these countries are in sub-Saharan Africa, Melanesia, South America, and",
      "extractCut": true
    },
    {
      "id": "sec-008-1-introduction",
      "number": "1",
      "title": "Introduction",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 20,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 562,
      "summary": {
        "text": "Reviews cervical screening methods, noting that cytology programmes have greatly cut mortality in some countries but have been less successful in low- and middle-income settings, and describes newer VIA and HPV DNA tests and tests under evaluation. A table groups molecular, cytologic and visual inspection tests, and the text explains the screen-and-treat approach, preferably in a single visit.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "triage test",
          "heading": false
        },
        {
          "term": "visual inspection",
          "heading": false
        },
        {
          "term": "high-risk hpv",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "visual evaluation",
          "heading": false
        }
      ],
      "extract": "2 Launch page: https://www.who.int/news-room/events/detail/2020/11/17/default-calendar/launch-of-the-global-strategy-to-accelerate- the-elimination-of-cervical-cancer The traditional method to screen women for cervical cancer has been cytology (the Papanicolaou test, also known as the Pap smear or smear test). When cytology results are positive, the diagnosis is confirmed by colposcopy, and appropriate treatment is",
      "extractCut": true
    },
    {
      "id": "sec-009-12-approaches-to-screening-and-treatment",
      "number": "1.2",
      "title": "Approaches to screening and treatment",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 78,
      "summary": {
        "text": "Defines the two approaches compared in the guideline: screen-and-treat, where treatment follows a positive primary test, and screen, triage and treat, which requires a second positive triage test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "treat approach",
          "heading": false
        },
        {
          "term": "screen-and-treat approach",
          "heading": false
        }
      ],
      "extract": "In this document, two approaches to screening and treatment are distinguished: the screen-and-treat approach and the screen, triage and treat approach. Screening and treatment approaches • In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only. • In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test",
      "extractCut": true
    },
    {
      "id": "sec-010-13-rationale-for-this-new-edition-of-recommendat",
      "number": "1.3",
      "title": "Rationale for this new edition of recommendations",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 351,
      "summary": {
        "text": "Explains that earlier WHO cervical screening and treatment recommendations were spread across several guidelines and the 2014 comprehensive guide, and that this edition updates them in light of new evidence and the elimination strategy. It states the guideline's objective of improving national screening and treatment strategies for all women, including those living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "thermal ablation",
          "heading": false
        },
        {
          "term": "prevent cervical",
          "heading": false
        },
        {
          "term": "pre-cancer lesions",
          "heading": false
        },
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "cin",
          "heading": false
        }
      ],
      "extract": "Recommendations for screening and treatment to prevent cervical cancer, including for women living with HIV, can be found in four existing WHO guidelines – on screening and treatment of pre-cancer lesions, treatment for CIN2/3 and AIS, cryotherapy for CIN, and thermal ablation for pre-cancer lesions (12–15). These recommendations (except for those on thermal ablation, published later in 2019) were consolidated in",
      "extractCut": true
    },
    {
      "id": "sec-011-14-phased-approach-for-the-development-of-the-re",
      "number": "1.4",
      "title": "Phased approach for the development of the recommendations",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 274,
      "summary": {
        "text": "Outlines the four phases of updating WHO's cervical screening recommendations, from updating key algorithms (this guideline) to evaluating others, implementation guidance and a living guideline. It notes that the guideline also aims to clarify starting age, lifetime screens and screening intervals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "clinical algorithms",
          "heading": false
        },
        {
          "term": "phase",
          "heading": false
        },
        {
          "term": "treatment",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": false
        },
        {
          "term": "living",
          "heading": false
        },
        {
          "term": "recommended",
          "heading": false
        }
      ],
      "extract": "The following are the four phases of the updates to WHO’s cervical cancer screening and treatment recommendations. This guideline delivers the output of Phase 1. Update the recommendations on screening and treatment and the clinical algorithms for the most commonly used screening and triage strategies for both women in general and those living with HIV. Evaluate the evidence for the clinical algorithms that were not",
      "extractCut": true
    },
    {
      "id": "sec-012-15-target-audience",
      "number": "1.5",
      "title": "Target audience",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 247,
      "summary": {
        "text": "Identifies the guideline's audience as policy-makers, programme managers and health professionals involved in cervical cancer prevention, and notes that the term women is used for all people at risk of cervical cancer regardless of gender identity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cisgender women",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        },
        {
          "term": "prevention services",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "gender",
          "heading": false
        },
        {
          "term": "recognize",
          "heading": false
        }
      ],
      "extract": "This document is intended primarily for policy-makers, programme managers, programme officers and other professionals in the health sector who have responsibility for choosing strategies for cervical cancer prevention, at country, regional and district levels. Health-care professionals – such as doctors, nurses and community health workers working in reproductive health programmes, antenatal and postnatal services,",
      "extractCut": true
    },
    {
      "id": "sec-013-2-methods",
      "number": "2",
      "title": "Methods",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 15,
      "summary": {
        "text": "A short lead-in stating that the guideline followed the WHO handbook for guideline development and summarising the process.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "handbook for guideline development, second edition (18). A summary of the process is provided here.",
      "extractCut": false
    },
    {
      "id": "sec-014-21-groups-contributing-to-the-guideline-developm",
      "number": "2.1",
      "title": "Groups contributing to the guideline development process",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 468,
      "summary": {
        "text": "Describes the groups involved in developing the guideline, including the WHO and IARC Secretariat, Steering Group, Guideline Development Group, External Review Group and systematic review and modelling teams. It notes that much of the work was done virtually through online meetings, surveys and shared platforms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "guideline development",
          "heading": true
        },
        {
          "term": "gdg members",
          "heading": false
        },
        {
          "term": "gdg meetings",
          "heading": false
        },
        {
          "term": "review teams",
          "heading": false
        },
        {
          "term": "modelling teams",
          "heading": false
        },
        {
          "term": "steering group",
          "heading": false
        },
        {
          "term": "evidence reviews",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        }
      ],
      "extract": "Lists of all members of the Guideline Development Group (GDG), External Review Group (ERG), systematic review teams, modelling teams and other contributors are provided in Annex 1, with details of their expertise and affiliations. The WHO Secretariat consisted of staff from various relevant WHO departments, and staff from the International Agency for Research on Cancer (IARC). The Steering Group of the WHO",
      "extractCut": true
    },
    {
      "id": "sec-015-declarations-and-management-of-conflicts-of-inte",
      "number": null,
      "title": "Declarations and management of conflicts of interest",
      "level": 3,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 129,
      "summary": {
        "text": "Explains that Guideline Development Group members completed declarations of interest, which were reviewed and found to raise no conflicts, and were asked to report new interests at each meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gdg members",
          "heading": false
        },
        {
          "term": "conflicts",
          "heading": true
        },
        {
          "term": "interest",
          "heading": true
        },
        {
          "term": "guideline development",
          "heading": false
        }
      ],
      "extract": "After being invited to join the GDG by the WHO Secretariat at the beginning of the guideline development process, and in accordance with the WHO handbook for guideline development (18), each prospective GDG member completed a written declaration of interest (DOI) form. The DOIs were reviewed by two members of the WHO Secretariat and no conflicts of interest were identified (Annex 3). The GDG members’ names and",
      "extractCut": true
    },
    {
      "id": "sec-016-confidentiality",
      "number": null,
      "title": "Confidentiality",
      "level": 3,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 39,
      "summary": {
        "text": "Notes that group members signed confidentiality agreements and that discussions and draft recommendations were kept confidential until publication.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidentiality",
          "heading": true
        },
        {
          "term": "gdg",
          "heading": false
        },
        {
          "term": "until",
          "heading": false
        }
      ],
      "extract": "Each GDG member also signed a confidentiality agreement at the beginning of the GDG process, and the WHO Secretariat restated at the start of each GDG meeting that all discussions and draft recommendations were to remain confidential until publication.",
      "extractCut": false
    },
    {
      "id": "sec-017-22-scoping-review-and-appraisal-of-the-existing",
      "number": "2.2",
      "title": "Scoping review and appraisal of the existing recommendations",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 147,
      "summary": {
        "text": "Describes the October 2019 scoping review of existing recommendations to decide which to remove, validate, update or add, and the approval of separate then merged scoping documents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "scoping",
          "heading": true
        },
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "grc",
          "heading": false
        },
        {
          "term": "approved",
          "heading": false
        }
      ],
      "extract": "In October 2019, a subgroup of the GDG met in Geneva to review the previously published recommendations and decide which should be removed, validated, edited or updated based on new evidence, and whether any new recommendations should be made for new interventions. This process was informed by a scoping review of the literature and an assessment of changes in disease burden, practice and policy. These decisions were",
      "extractCut": true
    },
    {
      "id": "sec-018-23-priority-questions-for-review-of-evidence",
      "number": "2.3",
      "title": "Priority questions for review of evidence",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 28,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 290,
      "summary": {
        "text": "Presents the 14 PICO questions guiding the evidence review, covering comparisons of screen-and-treat and triage strategies, follow-up intervals, starting age and strategies to support screening uptake, some deferred to a later phase.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "screening approaches",
          "heading": false
        },
        {
          "term": "screen-and-treat strategy",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "treat strategy",
          "heading": false
        },
        {
          "term": "strategy versus",
          "heading": false
        },
        {
          "term": "versus another",
          "heading": false
        }
      ],
      "extract": "The GDG identified 14 overarching questions, framed using the population (P), intervention (I), comparator (C), outcomes (O) (PICO) format, as a starting point for formulating recommendations applying to the general population of women and women living with HIV (Table 2.1). PICO 1 Should one screen-and-treat strategy versus another screen-and-treat strategy be used in women? PICO 2 Should one screen, triage and",
      "extractCut": true
    },
    {
      "id": "sec-019-24-priority-algorithms",
      "number": "2.4",
      "title": "Priority algorithms",
      "level": 2,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 95,
      "summary": {
        "text": "Explains that a survey and subgroup meeting in December 2019 narrowed the many possible screening and triage combinations to seven priority algorithms for this phase.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "algorithms",
          "heading": true
        },
        {
          "term": "triage tests",
          "heading": false
        },
        {
          "term": "gdg members",
          "heading": false
        }
      ],
      "extract": "Since screening and treatment can be done using different primary screening and triage tests, there are numerous possible combinations or algorithms. In December 2019, GDG members were surveyed to prioritize the screening and/or triage tests and the treatments that should be evaluated. Following this prioritization exercise, a subgroup of GDG members met to review the results from the survey and to agree on the",
      "extractCut": true
    },
    {
      "id": "sec-020-25-outcomes",
      "number": "2.5",
      "title": "Outcomes",
      "level": 2,
      "pageStart": 28,
      "pageEnd": 29,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 340,
      "summary": {
        "text": "Lists the critical outcomes carried over from the 2013 guideline, including cancer incidence and mortality, detection of pre-cancer, preterm birth and grouped adverse events of treatment, along with costs, feasibility and equity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "colposcopy triage",
          "heading": false
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "dna detection",
          "heading": false
        },
        {
          "term": "pre-cancer treatment",
          "heading": false
        },
        {
          "term": "primary screening",
          "heading": false
        },
        {
          "term": "outcomes",
          "heading": true
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "critical outcomes",
          "heading": false
        }
      ],
      "extract": "The GDG agreed that the outcomes previously identified in the 2013 screening and treatment guideline (12) would also be the critical outcomes for the new PICO questions; the critical outcomes are listed in Table 2.3. To ensure coherence in the systematic reviews and modelling, a working group (subgroup of the GDG) developed standardized definitions for these outcomes (see Annex 5). After reviewing the evidence and",
      "extractCut": true
    },
    {
      "id": "sec-021-26-syntheses-of-evidence",
      "number": "2.6",
      "title": "Syntheses of evidence",
      "level": 2,
      "pageStart": 29,
      "pageEnd": 32,
      "labelStart": "12",
      "labelEnd": "15",
      "words": 815,
      "summary": {
        "text": "Describes how evidence was synthesised using WHO and Cochrane methods, drawing on the forthcoming IARC handbook and updating existing reviews where possible. A table maps each type of evidence, such as systematic reviews, modelling and surveys, to the related recommendations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "etd pico",
          "heading": false
        },
        {
          "term": "iarc handbook",
          "heading": false
        },
        {
          "term": "to-decision tables",
          "heading": false
        },
        {
          "term": "evidence to-decision",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "pico age",
          "heading": false
        },
        {
          "term": "syntheses",
          "heading": true
        },
        {
          "term": "cervical cancer",
          "heading": false
        }
      ],
      "extract": "Evidence was synthesized for each PICO question according to the methods in the WHO handbook for guideline development and the Cochrane handbook for systematic reviews of interventions (18,20). The literature review performed for the development of the IARC handbooks of cancer prevention: cervical cancer screening, Vol. 18 (to be published in 2021; referred to in brief throughout this guideline as “IARC handbook”)",
      "extractCut": true
    },
    {
      "id": "sec-022-261-methods-used-for-systematic-literature-revie",
      "number": "2.6.1",
      "title": "Methods used for systematic literature reviews",
      "level": 3,
      "pageStart": 32,
      "pageEnd": 33,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 371,
      "summary": {
        "text": "Summarises the methods used in the systematic reviews, from protocols and database searches to risk-of-bias assessment, synthesis and GRADE certainty ratings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systematic reviews",
          "heading": true
        },
        {
          "term": "effect estimate",
          "heading": false
        },
        {
          "term": "true effect",
          "heading": false
        },
        {
          "term": "reviewer",
          "heading": false
        },
        {
          "term": "exclusion criteria",
          "heading": false
        },
        {
          "term": "duplicate",
          "heading": false
        },
        {
          "term": "verified",
          "heading": false
        },
        {
          "term": "studies based",
          "heading": false
        }
      ],
      "extract": "The detailed methods for each review are reported in the Annex A, Supplementary Materials (Table 2.4). In brief, the systematic review teams applied the following key methods across all systematic reviews for this guideline: • develop a systematic review protocol with inclusion and exclusion criteria for studies based on the finalized PICO questions; • search multiple databases (including MEDLINE, Embase and the",
      "extractCut": true
    },
    {
      "id": "sec-023-262-individual-patient-data-meta-analysis",
      "number": "2.6.2",
      "title": "Individual patient data meta-analysis",
      "level": 3,
      "pageStart": 33,
      "pageEnd": 34,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 147,
      "summary": {
        "text": "Describes an individual patient data meta-analysis of age-specific cervical lesion data in women living with HIV, using random-effects models to estimate screening results by age and HIV status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical screening",
          "heading": false
        },
        {
          "term": "supplementary material",
          "heading": false
        },
        {
          "term": "ipd-ma",
          "heading": false
        },
        {
          "term": "sas",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        }
      ],
      "extract": "We conducted an individual patient data meta-analysis (IPD-MA) to analyse age-specific data for cervical cancer and CIN in women living with HIV. We contacted the authors of the studies identified in the systematic review of screening-initiation age (Web annex A, Supplementary material 5) that included at least 40 women living with HIV with CIN2+. All the data sets they provided were first reviewed individually,",
      "extractCut": true
    },
    {
      "id": "sec-024-263-mathematical-modelling",
      "number": "2.6.3",
      "title": "Mathematical modelling",
      "level": 3,
      "pageStart": 34,
      "pageEnd": 34,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 256,
      "summary": {
        "text": "Explains that the Policy1-Cervix model was used to project outcomes for 78 low- and middle-income countries, with an HIV-HPV model applied to the United Republic of Tanzania. Outcomes modelled included cancer incidence and mortality, treatments, preterm births and cost-effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "modelling",
          "heading": true
        },
        {
          "term": "policy1-cervix",
          "heading": false
        },
        {
          "term": "united republic",
          "heading": false
        },
        {
          "term": "middle-income countries",
          "heading": false
        },
        {
          "term": "control activities",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        }
      ],
      "extract": "We used the Policy1-Cervix platform, an extensively validated dynamic model of HPV transmission, vaccination, type-specific natural history, cancer survival, screening, diagnosis and treatment (23–31), to predict outcomes in women across all 78 low- and middle-income countries. The Policy-Cervix HIV-HPV model for cervical cancer among women living with HIV was used to evaluate outcomes for women living with HIV in",
      "extractCut": true
    },
    {
      "id": "sec-025-264-values-and-preferences",
      "number": "2.6.4",
      "title": "Values and preferences",
      "level": 3,
      "pageStart": 34,
      "pageEnd": 35,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 185,
      "summary": {
        "text": "Describes a literature search on values and preferences and an anonymous online survey of 561 women and girls run in English and French in 2020.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "survey",
          "heading": false
        },
        {
          "term": "preferences",
          "heading": true
        },
        {
          "term": "responses",
          "heading": false
        },
        {
          "term": "values",
          "heading": true
        },
        {
          "term": "women",
          "heading": false
        }
      ],
      "extract": "A search for studies and systematic reviews was conducted that addressed, among other considerations, the values and preferences of end-users, health-care providers and other stakeholders. The literature was organized by study design and methodology, location and population, and presented to the GDG. For primary data, all women and girls aged 15 years and older, regardless of their prior cervical cancer screening or",
      "extractCut": true
    },
    {
      "id": "sec-026-265-feasibility-acceptability-resources-and-equi",
      "number": "2.6.5",
      "title": "Feasibility, acceptability, resources and equity considerations",
      "level": 3,
      "pageStart": 35,
      "pageEnd": 35,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 180,
      "summary": {
        "text": "Describes a survey of Guideline Development Group members, using the CICI framework, on concerns about implementing each priority algorithm at scale across service components and stakeholder levels.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "priority algorithm",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "gdg members",
          "heading": false
        },
        {
          "term": "health authorities",
          "heading": false
        },
        {
          "term": "considerations",
          "heading": true
        },
        {
          "term": "survey",
          "heading": false
        }
      ],
      "extract": "A survey of the GDG members was administered via SurveyMonkey to assess the implementation considerations for each priority algorithm. The survey was developed using the context and implementation of complex interventions (CICI) framework (33). Each GDG member was asked about their level of concern about each algorithm being able to sustainably meet the large-scale goal of cervical cancer elimination. The following",
      "extractCut": true
    },
    {
      "id": "sec-027-27-development-of-the-recommendations",
      "number": "2.7",
      "title": "Development of the recommendations",
      "level": 2,
      "pageStart": 35,
      "pageEnd": 36,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 448,
      "summary": {
        "text": "Explains how evidence-to-decision tables were prepared and discussed virtually, how members gave input and voted through GRADEpro, and how recommendations were finalised. A table explains what strong and conditional recommendations mean for different audiences.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "etd tables",
          "heading": false
        },
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "conditional recommendations",
          "heading": false
        },
        {
          "term": "gdg meetings",
          "heading": false
        },
        {
          "term": "undesirable consequences",
          "heading": false
        },
        {
          "term": "gdg members",
          "heading": false
        },
        {
          "term": "desirable consequences",
          "heading": false
        },
        {
          "term": "decisions consistent",
          "heading": false
        }
      ],
      "extract": "All the GDG meetings that focused on formulation of recommendations were held virtually. Tables to facilitate decision-making for recommendations – evidence-to-decision (EtD) tables – were produced by the guideline methodologist for each recommendation and circulated to the GDG members before each meeting. These tables included a summary of the evidence (benefits and harms), relevant values and preferences",
      "extractCut": true
    },
    {
      "id": "sec-028-28-management-of-the-external-peer-review",
      "number": "2.8",
      "title": "Management of the external peer review",
      "level": 2,
      "pageStart": 36,
      "pageEnd": 37,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 246,
      "summary": {
        "text": "Describes how external peer review comments were handled and how good practice statements were used. It also notes that even one or two lifetime screens can reduce mortality where no routine programme exists and that implementation guidance will follow.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "guideline document",
          "heading": false
        },
        {
          "term": "erg",
          "heading": false
        },
        {
          "term": "review",
          "heading": true
        },
        {
          "term": "comments",
          "heading": false
        },
        {
          "term": "external",
          "heading": true
        },
        {
          "term": "secretariat",
          "heading": false
        }
      ],
      "extract": "The draft guideline document was circulated to the External Review Group (ERG) for comment. The WHO Secretariat prepared a summary table with all ERG responses and sorted the comments by topic or section. The WHO Secretariat then identified comments for discussion and presented these to the GDG, and when these issues had been resolved via email correspondence, the guideline document was finalized. Table 2.6",
      "extractCut": true
    },
    {
      "id": "sec-029-31-programme-considerations",
      "number": "3.1",
      "title": "Programme considerations",
      "level": 2,
      "pageStart": 37,
      "pageEnd": 37,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 221,
      "summary": {
        "text": "Advises that a multidisciplinary ministry team choose national screening algorithms according to resources, feasibility and acceptability, and distinguishes clinical scenarios for follow-up such as regular screening intervals. It encourages population-based programmes that ensure treatment of women who screen positive.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening intervals",
          "heading": false
        },
        {
          "term": "regular screening",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "women",
          "heading": false
        },
        {
          "term": "follow-up",
          "heading": false
        },
        {
          "term": "programme",
          "heading": true
        },
        {
          "term": "decisions",
          "heading": false
        }
      ],
      "extract": "It is appropriate that a multidisciplinary health ministry team, which can consider different factors and make informed decisions, chooses which algorithm (or algorithms) to include in a national programme. The choice will vary by country – and in different settings within country programmes – and will depend on available resources, feasibility and acceptability. Decisions are also needed about when and who to",
      "extractCut": true
    },
    {
      "id": "sec-030-3-important-considerations-for-the-recommendatio",
      "number": "3",
      "title": "Important considerations for the recommendations",
      "level": 1,
      "pageStart": 37,
      "pageEnd": 38,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 172,
      "summary": {
        "text": "Stresses screening registries, call-and-recall and links between care levels, and states that screening and treatment should be offered to transgender men, non-binary and intersex people with a cervix, with services made more inclusive.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "intersex",
          "heading": false
        },
        {
          "term": "non-binary",
          "heading": false
        },
        {
          "term": "transgender",
          "heading": false
        }
      ],
      "extract": "recommendations and call-and-recall efforts are important aspects of appropriate management to ensure that women are coming back to the service for treatment and follow-up. For the continuity and completeness of care, strong links need to be established between the multiple levels of the health service (primary and secondary care) and individual patients. A further description of quality assurance and more detailed",
      "extractCut": true
    },
    {
      "id": "sec-031-32-screening-and-triage-tests-considered-in-thes",
      "number": "3.2",
      "title": "Screening and triage tests considered in these guidelines",
      "level": 2,
      "pageStart": 38,
      "pageEnd": 40,
      "labelStart": "21",
      "labelEnd": "23",
      "words": 739,
      "summary": {
        "text": "Describes the screening and triage tests considered, including high-risk HPV DNA tests with partial or extended genotyping, cytology, VIA and colposcopy. It explains how they are combined in algorithms, such as HPV testing followed by VIA triage to decide treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "triage tests",
          "heading": true
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "hpv genotypes",
          "heading": false
        },
        {
          "term": "high-risk hpv",
          "heading": false
        },
        {
          "term": "partial genotyping",
          "heading": false
        },
        {
          "term": "acetic acid",
          "heading": false
        },
        {
          "term": "ablative treatment",
          "heading": false
        },
        {
          "term": "carcinogenic types",
          "heading": false
        }
      ],
      "extract": "High-risk HPV DNA tests: These tests identify a group of high-risk carcinogenic HPV genotypes, typically including up to 14 types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59, which are Group 1 carcinogens, and HPV66 and 68) (37). HPV16 and 18 are the highest-risk genotypes and are the most common in cancers. Some of the tests on the market provide information about specific HPV genotypes, such as HPV16 and",
      "extractCut": true
    },
    {
      "id": "sec-032-33-treatment-considerations",
      "number": "3.3",
      "title": "Treatment considerations",
      "level": 2,
      "pageStart": 40,
      "pageEnd": 41,
      "labelStart": "23",
      "labelEnd": "24",
      "words": 338,
      "summary": {
        "text": "Explains treatment options for cervical pre-cancer, distinguishing ablative methods (thermal ablation, cryotherapy) from excisional ones (LLETZ, cold knife conization), and restates the count of recommendations and good practice statements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "transformation zone",
          "heading": false
        },
        {
          "term": "ablative therapy",
          "heading": false
        },
        {
          "term": "abnormal tissue",
          "heading": false
        },
        {
          "term": "tissue specimen",
          "heading": false
        },
        {
          "term": "lletz",
          "heading": false
        },
        {
          "term": "treatment",
          "heading": true
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "practice statements",
          "heading": false
        }
      ],
      "extract": "In a screen-and-treat approach, women who screen positive are treated without histological diagnosis. The treatment aims to destroy or remove the transformation zone of the cervix, or remove areas of the cervix that have been identified as abnormal by screening. The methods of treatment may be ablative (destroying abnormal tissue by heating it with thermal coagulation or freezing it with cryotherapy) or excisional",
      "extractCut": true
    },
    {
      "id": "sec-033-4-recommendations-and-good-practice-statements-o",
      "number": "4",
      "title": "Recommendations and good practice statements on screening and treatment",
      "level": 1,
      "pageStart": 41,
      "pageEnd": 44,
      "labelStart": "24",
      "labelEnd": "27",
      "words": 983,
      "summary": {
        "text": "Sets out the recommendations and good practice statements for the general population of women, starting with HPV DNA detection as the preferred primary screening test and covering triage, sample collection, age to start and stop screening, intervals and follow-up. It ends with the summary strategy of HPV DNA screening from age 30 every 5 to 10 years, with or without triage.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "practice statements",
          "heading": true
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "dna test",
          "heading": false
        },
        {
          "term": "dna primary",
          "heading": false
        },
        {
          "term": "suggests regular",
          "heading": false
        },
        {
          "term": "dna detection",
          "heading": false
        },
        {
          "term": "until hpv",
          "heading": false
        }
      ],
      "extract": "of women (section 4.1, nos. 1–14) and then for women living with HIV (section 4.2, nos. 21–34), and finally an additional recommendation and good practice statement regarding treatment for all women are presented (section 4.3, nos. 41 and 42).5 4.1 Recommendations and good practice statements: general population of women6 All screening algorithms are in Annex 4. 1. WHO recommends using HPV DNA detection as the",
      "extractCut": true
    },
    {
      "id": "sec-034-411-justification",
      "number": "4.1.1",
      "title": "Justification",
      "level": 3,
      "pageStart": 44,
      "pageEnd": 45,
      "labelStart": "27",
      "labelEnd": "28",
      "words": 435,
      "summary": {
        "text": "Explains the justification for the recommendations, chiefly the greater reductions in cancer and deaths with HPV DNA testing than with VIA or cytology, possible fewer harms and the acceptability of provider or self-sampling. It also justifies the chosen starting age, intervals and follow-up timings, based mostly on low-certainty evidence and modelling.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "dna detection",
          "heading": false
        },
        {
          "term": "dna test",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "screening intervals",
          "heading": false
        },
        {
          "term": "dna testing",
          "heading": false
        },
        {
          "term": "fewer harms",
          "heading": false
        },
        {
          "term": "triage test",
          "heading": false
        }
      ],
      "extract": "A strong recommendation was made for using HPV DNA detection as a primary screening test when part of a screen-and-treat approach or a screen, triage and treat approach because a higher value was placed on the greater reductions in cervical cancer and deaths that are likely with HPV DNA detection compared with using VIA or cytology as a primary screening test (moderate- certainty evidence). There may also be fewer",
      "extractCut": true
    },
    {
      "id": "sec-035-412-summary-of-the-evidence",
      "number": "4.1.2",
      "title": "Summary of the evidence",
      "level": 3,
      "pageStart": 45,
      "pageEnd": 48,
      "labelStart": "28",
      "labelEnd": "31",
      "words": 2004,
      "summary": {
        "text": "Summarises the evidence behind the cervical screening recommendations for the general population of women, finding moderate-certainty evidence from trials and modelling that HPV DNA testing reduces pre-cancer, advanced cancer and deaths more than VIA, with lower risk after a negative HPV test than after negative cytology. It reports similar benefits for screen-and-treat and triage approaches, slightly fewer cancers with HPV16/18 genotyping triage, and likely similar performance of self-collected samples. It reviews evidence on starting screening at 30 versus 35, stopping age, screening intervals and follow-up timing, weighing benefits against treatments, preterm births and costs. It notes practical concerns about longer follow-up intervals and the transition from VIA or cytology to HPV testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "dna screening",
          "heading": false
        },
        {
          "term": "hpv genotyping",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "dna test",
          "heading": false
        },
        {
          "term": "dna testing",
          "heading": false
        },
        {
          "term": "supplementary material",
          "heading": false
        },
        {
          "term": "triage test",
          "heading": false
        }
      ],
      "extract": "For further details on the following, refer to the summaries in Web annex A (Syntheses of the evidence) and Web annex B (EtD tables) – web links provided at the end of the Table of Contents. Primary screening tests (Recommendations 1, 3 and 4): The GDG considered evidence for the effects of different primary screening tests and found moderate-certainty evidence from a synthesis of two randomized controlled trials",
      "extractCut": true
    },
    {
      "id": "sec-036-42-recommendations-and-good-practice-statements",
      "number": "4.2",
      "title": "Recommendations and good practice statements: women living with HIV",
      "level": 2,
      "pageStart": 48,
      "pageEnd": 51,
      "labelStart": "31",
      "labelEnd": "34",
      "words": 863,
      "summary": {
        "text": "Sets out the recommendations and good practice statements for women living with HIV, including HPV DNA primary screening, use of triage after a positive HPV test, triage options and provider or self-collected samples. It covers starting age, intervals and follow-up after treatment or negative triage, and ends with the summary strategy of HPV DNA screening with triage from age 25 every 3 to 5 years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "women living",
          "heading": true
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "suggests regular",
          "heading": false
        },
        {
          "term": "dna test",
          "heading": false
        },
        {
          "term": "dna primary",
          "heading": false
        },
        {
          "term": "until hpv",
          "heading": false
        }
      ],
      "extract": "with HIV7 21. WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.* [Strong recommendation, moderate-certainty evidence] Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational;",
      "extractCut": true
    },
    {
      "id": "sec-037-421-justification",
      "number": "4.2.1",
      "title": "Justification",
      "level": 3,
      "pageStart": 51,
      "pageEnd": 52,
      "labelStart": "34",
      "labelEnd": "35",
      "words": 472,
      "summary": {
        "text": "Justifies the recommendations for women living with HIV, citing the greater cancer and death reductions from HPV DNA testing, its acceptability and feasibility, and the reduced harms from adding triage. It also explains the chosen screening intervals and follow-up timings, mostly on low-certainty modelled evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "dna testing",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "cin lesions",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "screening intervals",
          "heading": false
        },
        {
          "term": "triage test",
          "heading": false
        },
        {
          "term": "moderate-certainty evidence",
          "heading": false
        }
      ],
      "extract": "For women living with HIV, a strong recommendation was made for using HPV DNA testing as a primary screening test because a higher value was placed on the reductions in cervical cancer and deaths that are likely with this approach than on the potential harm that may occur, such as preterm deliveries (moderate-certainty evidence). When compared with VIA or cytology as a primary screening test, greater benefits are",
      "extractCut": true
    },
    {
      "id": "sec-038-422-summary-of-the-evidence",
      "number": "4.2.2",
      "title": "Summary of the evidence",
      "level": 3,
      "pageStart": 52,
      "pageEnd": 55,
      "labelStart": "35",
      "labelEnd": "38",
      "words": 1657,
      "summary": {
        "text": "Summarises the evidence for the recommendations for women living with HIV, finding that HPV DNA primary screening likely reduces pre-cancer more than VIA and similarly to cytology, and that triage may reduce harms through fewer treatments. It reports modelled benefits of three- to five-year intervals, the likely validity of self-sampling, and a good practice statement to screen at least twice in a lifetime. It also reviews individual patient data and modelling on starting age, follow-up intervals and uncertainties in applying general population results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "hpv dna-based",
          "heading": false
        },
        {
          "term": "cytology followed",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "dna testing",
          "heading": false
        },
        {
          "term": "dna test",
          "heading": false
        },
        {
          "term": "hpv genotyping",
          "heading": false
        },
        {
          "term": "supplementary material",
          "heading": false
        }
      ],
      "extract": "For further details on the following, refer to the summaries in Web annex A (Syntheses of the evidence) and Web annex B (EtD tables) – web links provided at the end of the Table of Contents. Primary screening tests (Recommendations 21, 23 and 24): Moderate-certainty evidence from a randomized controlled trial, longitudinal studies and modelling found that HPV DNA as the primary screening test in screening and",
      "extractCut": true
    },
    {
      "id": "sec-039-43-additional-recommendation-and-good-practice-s",
      "number": "4.3",
      "title": "Additional recommendation and good practice statement for treatment not covered",
      "level": 2,
      "pageStart": 55,
      "pageEnd": 55,
      "labelStart": "38",
      "labelEnd": "38",
      "words": 179,
      "summary": {
        "text": "Gives a good practice statement to treat women within six months of a decision to treat (deferring until after pregnancy and re-evaluating if delayed) and a conditional recommendation for LLETZ or cold knife conization for adenocarcinoma in situ.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "practice",
          "heading": true
        },
        {
          "term": "lletz",
          "heading": false
        },
        {
          "term": "treatment",
          "heading": true
        },
        {
          "term": "general population",
          "heading": false
        },
        {
          "term": "ckc",
          "heading": false
        }
      ],
      "extract": "for treatment not covered in previous guidelines for the general population of women and women living with HIV 41. Once a decision to treat a woman is made – whether from the general population of women or women living with HIV – it is good practice to treat as soon as possible within six months to reduce the risk of loss to follow-up. However, in women who are pregnant, good practice includes deferral until after",
      "extractCut": true
    },
    {
      "id": "sec-040-431-justification-and-evidence-summary",
      "number": "4.3.1",
      "title": "Justification and evidence summary",
      "level": 3,
      "pageStart": 55,
      "pageEnd": 56,
      "labelStart": "38",
      "labelEnd": "39",
      "words": 531,
      "summary": {
        "text": "Summarises low-certainty evidence showing little difference in recurrence or complications between cold knife conization and loop excision for adenocarcinoma in situ, but more preterm births after conization, which is also costlier and less accessible. It then lists research gaps on HPV genotyping, screening strategies and starting age for women living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "electrosurgical excision",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "recurrence rate",
          "heading": false
        },
        {
          "term": "cervical pre-cancer",
          "heading": false
        },
        {
          "term": "ckc",
          "heading": false
        },
        {
          "term": "evidence",
          "heading": true
        },
        {
          "term": "gdg",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        }
      ],
      "extract": "Low-certainty evidence from a systematic review of the literature found that there may be little to no difference in the recurrence rate of AIS with CKC or electrosurgical excision, or in the incidence of complications such as major infection and bleeding, and found that more women may have premature deliveries in subsequent pregnancies following a CKC compared with electrosurgical excision. The studies included in",
      "extractCut": true
    },
    {
      "id": "sec-041-5-research-gaps-and-further-considerations",
      "number": "5",
      "title": "Research gaps and further considerations",
      "level": 1,
      "pageStart": 56,
      "pageEnd": 58,
      "labelStart": "39",
      "labelEnd": "41",
      "words": 188,
      "summary": {
        "text": "Notes further research gaps, including treatment of adenocarcinoma in situ in women living with HIV, cost-effectiveness of excision methods, integrating screening into HIV programmes, loss to follow-up after positive screening, and training costs when moving to HPV testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "research gaps",
          "heading": true
        },
        {
          "term": "dna screening",
          "heading": false
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "lletz",
          "heading": false
        }
      ],
      "extract": "8 All the PICO questions are listed in Table 2.1, in Chapter 2. Timing of treatment after positive screening or diagnosis (PICO 9 and 10) The GDG noted that in women living with HIV, more research is needed about the efficacy of CKC and LLETZ in the treatment of AIS. Evidence is needed for the costs and cost-effectiveness of CKC versus LLETZ for AIS in both the general population of women and in women living with",
      "extractCut": true
    },
    {
      "id": "sec-042-61-guideline-dissemination-and-impact",
      "number": "6.1",
      "title": "Guideline dissemination and impact",
      "level": 2,
      "pageStart": 58,
      "pageEnd": 58,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 414,
      "summary": {
        "text": "Describes plans to disseminate the cervical screening guideline through WHO networks, its website, printed copies, high-level meetings, conferences and policy briefs, with regional workshops to support national adaptation and partnership with UN agencies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": true
        },
        {
          "term": "regional offices",
          "heading": false
        },
        {
          "term": "dissemination",
          "heading": true
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "nations agencies",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "fund",
          "heading": false
        }
      ],
      "extract": "The final published guideline document will be disseminated using WHO's worldwide network to make sure that the guideline reaches health-care providers and programme managers so that the most recent evidence is integrated and accessible for clinical decision-making to prevent cervical cancer. A link to download the guideline will be available at the WHO website and in HRP News,9 and printed copies, if requested,",
      "extractCut": true
    },
    {
      "id": "sec-043-6-dissemination-and-updating-of-the-guidelines",
      "number": "6",
      "title": "Dissemination and updating of the guidelines",
      "level": 1,
      "pageStart": 58,
      "pageEnd": 59,
      "labelStart": "41",
      "labelEnd": "42",
      "words": 165,
      "summary": {
        "text": "Continues the dissemination plans, mentioning conferences and supporting WHO guidance, surveys of health workers and clients a year after release to measure impact, and a planned revision of WHO's comprehensive cervical cancer control guide.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "iaea",
          "heading": false
        },
        {
          "term": "subscribe",
          "heading": false
        },
        {
          "term": "energy",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": false
        }
      ],
      "extract": "9 Subscribe using the link at the end of this web page: https://www.who.int/reproductivehealth/news/en/ Energy Agency (IAEA) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) (39). The guideline will be disseminated at upcoming major conferences related to sexual and reproductive health and rights, HPV, HIV and public health. Other WHO guidance is available to support impact evaluation, national programme",
      "extractCut": true
    },
    {
      "id": "sec-044-62-guideline-update",
      "number": "6.2",
      "title": "Guideline update",
      "level": 2,
      "pageStart": 59,
      "pageEnd": 60,
      "labelStart": "42",
      "labelEnd": "43",
      "words": 177,
      "summary": {
        "text": "Explains that future versions will evaluate further tests such as HPV mRNA, DNA methylation, p16/Ki-67 dual staining and automated visual evaluation, and that Phase 4 will establish living recommendations updated as new evidence emerges.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "guideline update",
          "heading": true
        },
        {
          "term": "living recommendations",
          "heading": false
        },
        {
          "term": "syntheses",
          "heading": false
        },
        {
          "term": "algorithms",
          "heading": false
        },
        {
          "term": "methylation",
          "heading": false
        }
      ],
      "extract": "In this guideline, the GDG prioritized seven algorithms. Additional algorithms that will be covered in a future version of this guideline will include the use of HPV mRNA detection, DNA methylation, p16/Ki-67 dual-staining cytology and automated visual evaluation. Evidence for the sensitivity and specificity of these tests and the impact on important outcomes of using them in programmes is accumulating, and",
      "extractCut": true
    },
    {
      "id": "sec-045-references",
      "number": null,
      "title": "References",
      "level": 1,
      "pageStart": 60,
      "pageEnd": 64,
      "labelStart": "43",
      "labelEnd": "47",
      "words": 1232,
      "summary": {
        "text": "The reference list for the cervical pre-cancer screening and treatment guideline, citing mainly cancer statistics, WHO strategies and guidance, IARC monographs and screening studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cervical screening",
          "heading": false
        },
        {
          "term": "cancer elimination",
          "heading": false
        },
        {
          "term": "natl cancer",
          "heading": false
        },
        {
          "term": "cancer inst",
          "heading": false
        },
        {
          "term": "cervical intraepithelial",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "precancerous lesions",
          "heading": false
        }
      ],
      "extract": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:71:209–49. doi:10.3322/caac.21660. 2. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Heatlh Organization; 2020",
      "extractCut": true
    },
    {
      "id": "sec-046-annexes",
      "number": null,
      "title": "Annexes",
      "level": 1,
      "pageStart": 64,
      "pageEnd": 65,
      "labelStart": "47",
      "labelEnd": "48",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-047-annex-1-guideline-groups",
      "number": null,
      "title": "Annex 1: Guideline groups",
      "level": 2,
      "pageStart": 65,
      "pageEnd": 75,
      "labelStart": "48",
      "labelEnd": "58",
      "words": 1646,
      "summary": {
        "text": "Annex 1, listing members of the Guideline Development Group by WHO region and institution, along with other contributors and the WHO and IARC Secretariat.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cancer institute",
          "heading": false
        },
        {
          "term": "south-east asia",
          "heading": false
        },
        {
          "term": "cancer centre",
          "heading": false
        },
        {
          "term": "western pacific",
          "heading": false
        },
        {
          "term": "eastern mediterranean",
          "heading": false
        },
        {
          "term": "cancer center",
          "heading": false
        },
        {
          "term": "council nsw",
          "heading": false
        },
        {
          "term": "national cancer",
          "heading": false
        }
      ],
      "extract": "Guideline Development Group (GDG) members GDG Co-Chairs: Julie Torode and Mike Chirenje WHO region Last name First name Institution Country African Achieng Claire Judith Ikate Uganda Cancer Society Uganda African Awori Ruth Representative from communities of women living with HIV Uganda African Chinula Lameck Kamuzu Central Hospital Malawi African Chirenje Mike University of Zimbabwe Zimbabwe African Chung Michael",
      "extractCut": true
    },
    {
      "id": "sec-048-annex-2-evidence-gathering-teams-and-guideline-t",
      "number": null,
      "title": "Annex 2. Evidence-gathering teams and guideline task groups",
      "level": 2,
      "pageStart": 75,
      "pageEnd": 77,
      "labelStart": "58",
      "labelEnd": "60",
      "words": 393,
      "summary": {
        "text": "Annex 2, a table of the evidence-gathering teams and task groups for each set of PICO questions, naming leads and members for reviews, modelling and the IARC handbook.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "partha basu",
          "heading": false
        },
        {
          "term": "nancy santesso",
          "heading": false
        },
        {
          "term": "maribel almonte",
          "heading": false
        },
        {
          "term": "karen canfell",
          "heading": false
        },
        {
          "term": "neerja bhatla",
          "heading": false
        },
        {
          "term": "jose jeronimo",
          "heading": false
        },
        {
          "term": "walter prendiville",
          "heading": false
        },
        {
          "term": "raul murillo",
          "heading": false
        }
      ],
      "extract": "PICO 1 and 2 PICO 1 and 2 PICO 3, 4, 5, 6, 7, 8 PICO 3, 4, 7, 8 PICO 9, 10 Screen- and-treat Screen, triage and treat (follow-up studies) Screen- and-treat Screen, triage and treat (diagnostic studies) Follow-up after positive or negative tests Follow-up after positive or negative tests in women living with HIV Duration between test and treatment Treatment of cervical intraepithelial neoplasia (severity) Lead:",
      "extractCut": true
    },
    {
      "id": "sec-049-annex-3-declarations-of-interests",
      "number": null,
      "title": "Annex 3. Declarations of interests",
      "level": 2,
      "pageStart": 77,
      "pageEnd": 80,
      "labelStart": "60",
      "labelEnd": "63",
      "words": 438,
      "summary": {
        "text": "Annex 3, a table showing that each Guideline Development Group member declared no interests and returned a confidentiality agreement.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interests declared",
          "heading": false
        },
        {
          "term": "americas",
          "heading": false
        },
        {
          "term": "received",
          "heading": false
        },
        {
          "term": "confidentiality agreement",
          "heading": false
        },
        {
          "term": "african",
          "heading": false
        },
        {
          "term": "european",
          "heading": false
        },
        {
          "term": "south-east",
          "heading": false
        },
        {
          "term": "myint",
          "heading": false
        }
      ],
      "extract": "Last name First name Declaration of interests Confidentiality agreement African Achieng Claire Judith Ikate No interests declared Received African Awori Ruth No interests declared Received African Chinula Lameck No interests declared Received African Chirenje Mike No interests declared Received African Chung Michael No interests declared Received African Denny Lynette No interests declared Received African Diop",
      "extractCut": true
    },
    {
      "id": "sec-050-annex-4-seven-algorithms-prioritized-for-phase-1",
      "number": null,
      "title": "Annex 4. Seven algorithms prioritized for Phase 1 of the guideline update",
      "level": 2,
      "pageStart": 80,
      "pageEnd": 90,
      "labelStart": "63",
      "labelEnd": "73",
      "words": 1385,
      "summary": {
        "text": "Annex 4, listing the seven screening algorithms prioritised for the first phase, two screen-and-treat and five screen, triage and treat, combining VIA, HPV DNA, cytology, genotyping and colposcopy. It presents flow diagrams for each algorithm for the general population and women living with HIV, including follow-up and re-treatment steps.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "thermal ablation",
          "heading": false
        },
        {
          "term": "colposcopy triage",
          "heading": false
        },
        {
          "term": "cin ais",
          "heading": false
        },
        {
          "term": "cytology triage",
          "heading": false
        },
        {
          "term": "ablative treatmenta",
          "heading": false
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "large-loop excision",
          "heading": false
        },
        {
          "term": "electrosurgical excision",
          "heading": false
        }
      ],
      "extract": "PRIORITIZED FOR PHASE 1 OF THE GUIDELINE UPDATE Screen-and-treat approaches: 1. Visual inspection with acetic acid (VIA) as the primary screening test, followed by treatment 2. HPV DNA (self- or clinician-collected) as the primary screening test, followed by treatment Screen, triage and treat approaches: 3. Cytology as the primary screening test, followed by colposcopy triage, followed by treatment 4. HPV DNA as the",
      "extractCut": true
    },
    {
      "id": "sec-051-annex-5-standardized-definitions-used-in-this-gu",
      "number": null,
      "title": "Annex 5. Standardized definitions used in this guideline",
      "level": 2,
      "pageStart": 90,
      "pageEnd": 112,
      "labelStart": "73",
      "labelEnd": "95",
      "words": 5559,
      "summary": {
        "text": "Annex 5, giving the standardised definitions used in the guideline, starting with eligibility for ablative treatment based on transformation zone type and lesion size and criteria for referral. It defines outcomes such as persistent, residual or recurrent disease and other clinical endpoints used in the reviews. It also defines the treatment methods, including thermal ablation, cryotherapy, LLETZ, cold knife conization and small-loop biopsy. Diagrams illustrate the three types of transformation zone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hsil cin",
          "heading": false
        },
        {
          "term": "squamous epithelium",
          "heading": false
        },
        {
          "term": "high-grade squamous",
          "heading": false
        },
        {
          "term": "transformation zone",
          "heading": false
        },
        {
          "term": "high-grade lesion",
          "heading": false
        },
        {
          "term": "histopathological high-grade",
          "heading": false
        },
        {
          "term": "histological hsil",
          "heading": false
        },
        {
          "term": "thermal ablation",
          "heading": false
        }
      ],
      "extract": "DEFINITIONS USED IN THIS GUIDELINE 5.1. Eligibility for ablative treatment Women who screen positive with a human papillomavirus (HPV) nucleic acid amplification test (NAAT) are assessed for eligibility for ablative treatment so that women with or without a visible lesion (or lesions), who are eligible for ablation, can receive an ablative treatment (see section 5.1.2). An assessment of eligibility for ablative",
      "extractCut": true
    },
    {
      "id": "sec-052-annex-6-additional-information-for-screening-and",
      "number": null,
      "title": "Annex 6. Additional information for screening and treatment recommendations",
      "level": 2,
      "pageStart": 112,
      "pageEnd": 115,
      "labelStart": "95",
      "labelEnd": "98",
      "words": 1347,
      "summary": {
        "text": "Annex 6, giving additional information on quality assurance, screening registries and call-and-recall, and describing the screening tests in more detail, including self-collection of samples, HPV nucleic acid tests and genotyping, cytology and VIA. It advises care in selecting clinically validated HPV tests and ends with footnoted references and WHO contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "swab brush",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cervical pre-cancer",
          "heading": false
        },
        {
          "term": "precancerous lesions",
          "heading": false
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "high-risk hpv",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "hpv types",
          "heading": false
        }
      ],
      "extract": "INFORMATION FOR SCREENING AND TREATMENT RECOMMENDATIONS Quality assurance: A quality-assured programme is one that is monitored to give assurance that the results consistently achieve the highest level of accuracy and reliability for the detection and treatment of cervical abnormalities by the modality chosen. Other programme information: Screening registries, and call-and-recall efforts to ensure that women are",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 5,
        "items": [
          "4.1 Recommendations and good practice statements: general population of women6",
          "4 Recommendations and good practice statements on screening and treatment to prevent cervical cancer",
          "5.2 Outcome definitions",
          "5.3 Outcome definitions: outcomes that required modelling",
          "5.4 Treatment definition"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [
      "table 1",
      "table 2.1"
    ],
    "pageLabelConflicts": {
      "count": 9,
      "items": [
        "p4: pdf-labels 4, printed iii",
        "p5: pdf-labels 5, printed iv",
        "p6: pdf-labels 6, printed v, contents v",
        "p7: pdf-labels 7, printed vi",
        "p8: pdf-labels 8, printed vii, contents vii",
        "p9: pdf-labels 9, printed viii, contents viii",
        "p10: pdf-labels 10, printed ix",
        "p11: pdf-labels 11, printed x, contents x",
        "p17: pdf-labels 17, printed xvi"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "cervical screening",
      "heading": true
    },
    {
      "term": "cervical cancer",
      "heading": true
    },
    {
      "term": "screening women",
      "heading": false
    },
    {
      "term": "hpv screening",
      "heading": true
    },
    {
      "term": "dna screening",
      "heading": true
    },
    {
      "term": "triage women",
      "heading": false
    },
    {
      "term": "screening test",
      "heading": true
    },
    {
      "term": "women living",
      "heading": true
    },
    {
      "term": "cervical pre-cancer",
      "heading": false
    },
    {
      "term": "primary screening",
      "heading": true
    },
    {
      "term": "screening algorithms",
      "heading": false
    },
    {
      "term": "follow-up screening",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "1",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "3",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "vi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "ix",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "13",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "15",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 17,
      "label": "xvi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 18,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "4",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "10",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 29,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 30,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "18",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 36,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 37,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 38,
      "label": "21",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 39,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "23",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 41,
      "label": "24",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 42,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "28",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "31",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 49,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "36",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "38",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 56,
      "label": "39",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 57,
      "label": "40",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "41",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 59,
      "label": "42",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 60,
      "label": "43",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 61,
      "label": "44",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "46",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "47",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 65,
      "label": "48",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 66,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "50",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 68,
      "label": "51",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "52",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 70,
      "label": "53",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 71,
      "label": "54",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 72,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 73,
      "label": "56",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 74,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 75,
      "label": "58",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 76,
      "label": "59",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 77,
      "label": "60",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 78,
      "label": "61",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 79,
      "label": "62",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 80,
      "label": "63",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 81,
      "label": "64",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 82,
      "label": "65",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 83,
      "label": "66",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 84,
      "label": "67",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 85,
      "label": "68",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 86,
      "label": "69",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 87,
      "label": "70",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 88,
      "label": "71",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 89,
      "label": "72",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 90,
      "label": "73",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 91,
      "label": "74",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 92,
      "label": "75",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 93,
      "label": "76",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 94,
      "label": "77",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 95,
      "label": "78",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 96,
      "label": "79",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 97,
      "label": "80",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 98,
      "label": "81",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 99,
      "label": "82",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 100,
      "label": "83",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 101,
      "label": "84",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 102,
      "label": "85",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 103,
      "label": "86",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 104,
      "label": "87",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 105,
      "label": "88",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 106,
      "label": "89",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 107,
      "label": "90",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 108,
      "label": "91",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 109,
      "label": "92",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 110,
      "label": "93",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 111,
      "label": "94",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 112,
      "label": "95",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 113,
      "label": "96",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 114,
      "label": "97",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 115,
      "label": "98",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "2",
      "title": "",
      "page": 11,
      "pageLabel": "x",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "2.2",
      "title": "The seven algorithms considered",
      "page": 28,
      "pageLabel": "11",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "box",
      "number": "3.1",
      "title": "Visual evaluation to assess eligibility for treatment",
      "page": 39,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "1",
      "title": "PRIMARY VIA SCREENING (SCREEN-AND-",
      "page": 81,
      "pageLabel": "64",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "2",
      "title": "PRIMARY HPV DNA TEST SCREENING",
      "page": 82,
      "pageLabel": "65",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "3",
      "title": "PRIMARY CYTOLOGY SCREENING AND",
      "page": 83,
      "pageLabel": "66",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "4",
      "title": "HPV DNA SCREENING AND HPV16/18",
      "page": 84,
      "pageLabel": "67",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "5",
      "title": "PRIMARY HPV DNA SCREENING AND VIA",
      "page": 85,
      "pageLabel": "68",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "6",
      "title": "PRIMARY HPV DNA SCREENING AND",
      "page": 86,
      "pageLabel": "69",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "algorithm",
      "number": "7",
      "title": "PRIMARY HPV SCREENING AND CYTOLOGY",
      "page": 87,
      "pageLabel": "70",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p110-1",
      "file": "images/img-p110-1.webp",
      "page": 110,
      "narratives": {
        "en": "Three schematic drawings of the cervix viewed from the front, stacked vertically: a pink circle with a central red area of varying size and position around the os, each with leader lines whose labels are not part of the image. In the surrounding annex text, such drawings accompany the description of transformation zone types 1, 2 and 3.",
        "ar": "ثلاثة رسوم تخطيطية لعنق الرحم من منظر أمامي، مرتبة عمودياً: دائرة وردية بداخلها منطقة حمراء مركزية متفاوتة الحجم والموضع حول فوهة عنق الرحم، ولكل منها خطوط إشارة لا تظهر تسمياتها في الصورة. وفي نص الملحق المحيط، تصاحب هذه الرسوم وصف أنواع منطقة التحول 1 و2 و3.",
        "zh": "三幅纵向排列的子宫颈正面示意图：粉色圆形中央有大小和位置各异、位于宫颈口周围的红色区域，每幅均带有引线，但其标签不在图像中。在周围的附件文字中，此类图示配合对1型、2型和3型转化区的描述。",
        "es": "Tres dibujos esquemáticos del cuello uterino en vista frontal, dispuestos verticalmente: un círculo rosa con una zona roja central de tamaño y posición variables alrededor del orificio cervical, cada uno con líneas de referencia cuyas etiquetas no forman parte de la imagen. En el texto del anexo, estos dibujos acompañan la descripción de los tipos 1, 2 y 3 de zona de transformación.",
        "fr": "Trois schémas du col de l’utérus vu de face, disposés verticalement : un cercle rose comportant une zone rouge centrale de taille et de position variables autour de l’orifice, chacun avec des lignes de repère dont les étiquettes ne figurent pas dans l’image. Dans le texte de l’annexe, ces schémas accompagnent la description des types 1, 2 et 3 de zone de remaniement.",
        "ru": "Три схематических изображения шейки матки во фронтальной проекции, расположенные вертикально: розовый круг с центральной красной областью разного размера и положения вокруг зева, у каждого — выносные линии, подписи к которым в изображение не входят. В окружающем тексте приложения такие рисунки сопровождают описание зон трансформации 1, 2 и 3 типов."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-2",
      "file": "images/img-p110-2.webp",
      "page": 110,
      "narratives": {
        "en": "Three schematic cross-section drawings of the cervix and cervical canal, stacked vertically, with red segments marking the epithelium at and inside the canal opening to differing extents and leader lines whose labels are not part of the image. They appear alongside the front-view drawings of transformation zone types 1, 2 and 3.",
        "ar": "ثلاثة رسوم تخطيطية لمقاطع عرضية لعنق الرحم وقناته، مرتبة عمودياً، مع أجزاء حمراء تشير إلى الظهارة عند فتحة القناة وداخلها بدرجات متفاوتة، وخطوط إشارة لا تظهر تسمياتها في الصورة. وتظهر إلى جانب الرسوم الأمامية لأنواع منطقة التحول 1 و2 و3.",
        "zh": "三幅纵向排列的子宫颈及宫颈管剖面示意图，红色线段标示宫颈管开口处及管内不同范围的上皮，并带有引线，但其标签不在图像中。这些图与1型、2型和3型转化区的正面示意图并列。",
        "es": "Tres dibujos esquemáticos en corte del cuello uterino y el conducto cervical, dispuestos verticalmente, con segmentos rojos que marcan el epitelio en la abertura del conducto y en su interior en distinta medida, y líneas de referencia cuyas etiquetas no forman parte de la imagen. Aparecen junto a los dibujos frontales de los tipos 1, 2 y 3 de zona de transformación.",
        "fr": "Trois schémas en coupe du col de l’utérus et du canal cervical, disposés verticalement, avec des segments rouges marquant l’épithélium à l’ouverture du canal et à l’intérieur, à des degrés divers, et des lignes de repère dont les étiquettes ne figurent pas dans l’image. Ils accompagnent les schémas de face des types 1, 2 et 3 de zone de remaniement.",
        "ru": "Три схематических изображения шейки матки и цервикального канала в разрезе, расположенные вертикально; красными сегментами в разной степени отмечен эпителий у входа в канал и внутри него, имеются выносные линии, подписи к которым в изображение не входят. Они расположены рядом с фронтальными изображениями зон трансформации 1, 2 и 3 типов."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 2",
      "caption": "Table 2. Recommendation and good practice statement for treatment not covered in previous guidelines",
      "pages": [
        16
      ],
      "columns": [
        {
          "titles": "For both the general population and women living with HIV"
        },
        {
          "titles": "Strength of recommendation and certainty of evidence"
        }
      ],
      "rows": [
        [
          "41. Once a decision to treat a woman is made – whether from the general population of women or women living with HIV – it is good practice to treat as soon as possible within six months to reduce the risk of loss to follow-up. However, in women who are pregnant, good practice includes deferral until after pregnancy.\nIn circumstances when treatment is not provided within this time frame, it is good practice to re-evaluate the woman before treatment.",
          "Good practice statement"
        ],
        [
          "42. WHO suggests large-loop excision of the transformation zone (LLETZ) or cold knife conization (CKC) for women from the general population and women living with HIV who have histologically confirmed adenocarcinoma in situ (AIS).\nRemarks: Loop excision may be preferred in women of reproductive age, in settings with greater availability of LLETZ and by providers with greater expertise performing LLETZ. CKC may be preferred when interpretation of the margins of the histological specimen is imperative.",
          "Conditional recommendation, low-certainty evidence"
        ]
      ],
      "notes": "The job pointed to page 11, which only mentions Table 2 in the text; the table itself is printed on page 16 (below the end of Table 1).\nFootnotes printed under the table (shared with Table 1): HPV: human papillomavirus; VIA: visual inspection with acetic acid.\na Rows shaded in blue indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column). In other rows, the wording of the recommendations differs for each population.",
      "narratives": {
        "en": "The table gives one good practice statement (no. 41, on the timing of treatment) and one recommendation (no. 42, on excision treatment for adenocarcinoma in situ) that apply to both the general population of women and women living with HIV, with the strength of recommendation and certainty of evidence.",
        "ar": "يعرض الجدول بيان ممارسة جيدة واحداً (رقم 41، بشأن توقيت العلاج) وتوصية واحدة (رقم 42، بشأن العلاج بالاستئصال للسرطانة الغدية الموضعية) ينطبقان على عموم النساء وعلى النساء المصابات بفيروس العوز المناعي البشري، مع بيان قوة التوصية ودرجة اليقين في البيّنات.",
        "zh": "该表列出一项良好实践声明（第41条，关于治疗时机）和一项建议（第42条，关于原位腺癌的切除治疗），二者均适用于一般女性人群和感染艾滋病毒的女性，并注明建议强度和证据确定性。",
        "es": "La tabla presenta una declaración de buenas prácticas (n.º 41, sobre el momento del tratamiento) y una recomendación (n.º 42, sobre el tratamiento por escisión del adenocarcinoma in situ) aplicables tanto a la población general de mujeres como a las mujeres con VIH, con la fuerza de la recomendación y la certeza de la evidencia.",
        "fr": "Le tableau présente une déclaration de bonne pratique (no 41, sur le délai de traitement) et une recommandation (no 42, sur le traitement par excision de l’adénocarcinome in situ) s’appliquant à la fois à la population générale des femmes et aux femmes vivant avec le VIH, avec la force de la recommandation et le degré de certitude des données.",
        "ru": "В таблице приведены одно положение о надлежащей практике (№ 41, о сроках лечения) и одна рекомендация (№ 42, о лечении аденокарциномы in situ путем иссечения), применимые как к женщинам из общей популяции, так и к женщинам, живущим с ВИЧ, с указанием силы рекомендации и степени достоверности данных."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 2.2",
      "caption": "Table 2.2. The seven algorithms considered",
      "pages": [
        28
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "Screen-and-treat approaches:",
          ""
        ],
        [
          "1",
          "VIA as the primary screening test, followed by treatment"
        ],
        [
          "2",
          "HPV DNA detection (self- or clinician-collected) as the primary screening test, followed by treatment"
        ],
        [
          "Screen, triage and treat approaches:",
          ""
        ],
        [
          "3",
          "Cytology as the primary screening test, followed by colposcopy triage, followed by treatment"
        ],
        [
          "4",
          "HPV DNA detection as the primary screening test, followed by HPV16/18 triage (when already part of the HPV test), followed by treatment, and using VIA triage for those who screen negative for HPV16/18"
        ],
        [
          "5",
          "HPV DNA detection as the primary screening test, followed by VIA triage, followed by treatment"
        ],
        [
          "6",
          "HPV DNA detection as the primary screening test, followed by colposcopy triage, followed by treatment"
        ],
        [
          "7",
          "HPV DNA detection as the primary screening test, followed by cytology triage, followed by colposcopy and treatment"
        ]
      ],
      "notes": "The table has no column header row; the two section headings (rows 1 and 4) span both columns.\nHPV: human papillomavirus; VIA: visual inspection with acetic acid.",
      "narratives": {
        "en": "The table lists the seven priority screening and treatment algorithms evaluated for the guideline, grouped into screen-and-treat approaches (1–2) and screen, triage and treat approaches (3–7).",
        "ar": "يسرد الجدول الخوارزميات السبع ذات الأولوية للتحرّي والعلاج التي جرى تقييمها لأغراض المبدأ التوجيهي، مقسّمة إلى نُهُج التحرّي والعلاج (1–2) ونُهُج التحرّي والفرز والعلاج (3–7).",
        "zh": "该表列出本指南评估的七种优先筛查和治疗算法，分为“筛查后治疗”方法（1–2）和“筛查、分诊后治疗”方法（3–7）。",
        "es": "La tabla enumera los siete algoritmos prioritarios de cribado y tratamiento evaluados para la directriz, agrupados en enfoques de cribado y tratamiento (1–2) y enfoques de cribado, triaje y tratamiento (3–7).",
        "fr": "Le tableau énumère les sept algorithmes prioritaires de dépistage et de traitement évalués pour la ligne directrice, regroupés en approches « dépister et traiter » (1–2) et « dépister, trier et traiter » (3–7).",
        "ru": "В таблице перечислены семь приоритетных алгоритмов скрининга и лечения, оцененных для руководства, сгруппированных в подходы «скрининг и лечение» (1–2) и «скрининг, сортировка и лечение» (3–7)."
      },
      "csv": "tables/table-2-2.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 54,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 54,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 2
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 2
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p60); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p8); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 53,
      "note": "53 of 54 sections"
    }
  ],
  "links": {
    "repo": "WorldHealthOrganization/who-iris",
    "branch": "main",
    "dir": "library/10665-342365"
  }
}
